<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Several <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> inhibitors are fragments of larger proteins that are themselves not active as <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> inhibitors </plain></SENT>
<SENT sid="1" pm="."><plain>Vasostatin, the N-terminal domain of calreticulin inclusive of amino acids 1-180, is an <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> inhibitor that exerts antitumor effects in vivo </plain></SENT>
<SENT sid="2" pm="."><plain>In the present study, we examined whether the full-length calreticulin molecule shares the antiangiogenic and antitumor activities of vasostatin </plain></SENT>
<SENT sid="3" pm="."><plain>Similar to vasostatin, calreticulin selectively inhibited endothelial cell proliferation in vitro, but not cells of other lineages, and suppressed <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> in vivo </plain></SENT>
<SENT sid="4" pm="."><plain>When inoculated into athymic mice, calreticulin inhibited <z:e sem="disease" ids="C0006413" disease_type="Neoplastic Process" abbrv="BL">Burkitt tumor</z:e> growth comparably with vasostatin </plain></SENT>
<SENT sid="5" pm="."><plain>Calreticulin lacking the N-terminal 1-120 amino acids inhibited endothelial cell proliferation in vitro and <z:e sem="disease" ids="C0006413" disease_type="Neoplastic Process" abbrv="BL">Burkitt tumor</z:e> growth in vivo comparably with vasostatin </plain></SENT>
<SENT sid="6" pm="."><plain>An internal calreticulin fragment encompassing amino acids 120-180 also inhibited endothelial cell proliferation in vitro and <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> in vivo comparably with calreticulin and vasostatin </plain></SENT>
<SENT sid="7" pm="."><plain>These results suggest that the antiangiogenic activities of vasostatin reside in a domain that is accessible from the full-length calreticulin molecule and localize to calreticulin N-terminal amino acids 120-180 </plain></SENT>
<SENT sid="8" pm="."><plain>Thus, calreticulin and calreticulin fragments are inhibitors of <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> that directly target endothelial cells, inhibit <z:mpath ids='MPATH_177'>angiogenesis</z:mpath>, and suppress <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>This information may be critical in designing targeted inhibitors of <z:mp ids='MP_0003711'>pathological angiogenesis</z:mp> that underlies <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and other diseases </plain></SENT>
</text></document>